Effects of common medications on cerebral vasospasm after subarachnoid haemorrhage

Expert Opinion on Drug Safety

Volumn 5, Issue 1, 2006, Pages 57-65

  Topcuoglu, Mehmet Akif ^a   Singhal, Aneesh B ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Aspirin; Calcium channel blocker; HMG coenzyme A reductase inhibitor; Nitric oxide (NO); Selective serotonin re uptake inhibitor (SSRI); Statin; Subarachnoid haemorrhage (SAH); Sympathomimetics; Vasospasm

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTIHYPERTENSIVE AGENT; ARGININE; ATORVASTATIN; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUNARIZINE; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; IRBESARTAN; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRIC OXIDE; NITRIC OXIDE DONOR; PAPAVERINE; PRAVASTATIN; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ANEURYSM RUPTURE; ANGIOPLASTY; ANTIHYPERTENSIVE ACTIVITY; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN VASCULITIS; BRAIN VASOSPASM; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY CONSTRICTION; CREATINE KINASE BLOOD LEVEL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HEART ARRHYTHMIA; HEMODILUTION; HUMAN; HYPOTENSION; INCIDENCE; INFLAMMATION; INTESTINE ISCHEMIA; KIDNEY FAILURE; LIVER DYSFUNCTION; LUNG EDEMA; MYOSITIS; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRESCRIPTION; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SHOCK; SIGNAL TRANSDUCTION; STROKE; SUBARACHNOID HEMORRHAGE; SYSTEMIC DISEASE; TACHYCARDIA; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITRIC OXIDE DONORS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SUBARACHNOID HEMORRHAGE; VASOSPASM, INTRACRANIAL;

EID: 30344465289     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.1.57     Document Type: Review

References (68)

1. TOPCUOGLU MA, PRYOR JC, OGILVY CS, KISTLER JP: Cerebral vasospasm following subarachnoid hemorrhage. Curr. Treat. Opt. Cardiovasc. Med. (2002) 4(5):373-384.
2. HARROD CG, BANDOK BR, BATJER HH: Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review. Neurosurgery (2005) 56:633-654.
3. FISHER CM, KISTLER JP, DAVIS JM: Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery (1980) 6:1-9.
4. HUNT WE, HESS RM: Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J. Neurosurg. (1968) 28:14-20.
5. MACDONALD RL, WEIR B: Medical aspects of vasospasm. In: Cerebral vasospasm. MacDonald Rl, Weir B (Ed.). Academic press. San Diego (2001):353-428.
6. DIETRICH HH, DACEY RG JR: Molecular keys to the problems of cerebral vasospasm. Neurosurgery (2000) 46:517-530.
7. MACDONALD RL, WEIR B: Pharmacology. In: Cerebral vasospasm. MacDonald Rl, Weir B (Ed.). Academic press. San Diego (2001):221-310.
8. ZUBKOV AY, NANDA A, ZHANG JH: Signal transduction pathways in cerebral vasospasm. Pathophysiology (2003) 9:47-61.
9. GRASSO G: An overview of new pharmacological treatments for cerebrovascular dysfunction after experimental subarachnoid hemorrhage. Brain Res. Rev. (2004) 44:49-63.
10. CLARK JF, PYNE-GEITHMAN G: Vascular smooth muscle function: The physiology and pathology of vasoconstriction. Pathophysiology (2005) 12:35-45.
11. SASAKI T, KASUYA H, ONDA H et al. Role of p38 mitogen-activated protein kinase on cerebral vasospasm after subarachnoid hemorrhage. Stroke (2004) 35:1466-1470.
12. PLUTA RM: Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacology Therapeutics (2005) 105:23-56.
13. LAHER I, ZHANG JH: Protein kinase C and cerebral vasospasm. J. Cereb. Blood Flow Metab. (2001) 21:887-906.
14. WICKMAN G, LAN C, VOLLRATH B: Functional roles of the rho/rho kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasospasm. Circ. Res. (2003) 92:809-816.
15. NISHIZAWA S, LAHER I: Signalling mechanism in cerebral vasospasm. Trends Cardiovasc. Med. (2005) 15:24-34.
16. PYNE GJ, CADOUX-HUDSON TAD, CLARK JF. Platelets play an essential role in the etiology of cerebral vasospasm after subarachnoid hemorrhage. Medical Hypotheses (2003) 60:525-530.
17. YU M, CAMJ-SAPUNAR L, KEHL F et al.: Effects of a 20-HETE antagonists and agonists on cerebral vascular tone. Eur. J. Pharmacol. (2004) 486:297-306.
18. HIROSE H, IDE K, SASAKI T et al.: The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog. Eur. J. Pharmacol. (1995) 277:77-87.
19. MACDONALD RL, WEIR B: Molecular biology and genetics. In: Cerebral Vasospasm. MacDonald Rl, Weir B (Ed.). Academic press, San Diego, USA (2001):476-508.
20. BOREL CO, MCKEE A, PARRA A et al.: Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. Stroke (2003) 34:427-433.
21. DUMONT AS, DUMONT RJ, CHOW MM et al.: Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery (2003) 53:123-135.
22. PRUNELL GF, SVENDGAARD NA, ALKASS K, MATHIESEN T: Inflammation in the brain after experimental subarachnoid hemorrhage. Neurosurgery (2005) 56:1082-1092.
23. CHEN D, NISHIZAWA S, YOKOTA N, OHTA S, YOKOYAMA T, NAMBA H: High-dose methylprednisolone prevents vasospasm after subarachnoid hemorrhage through inhibition of protein kinase C activation. Neurol. Res. (2002) 24:215-122.
24. RINKEL GJ, FEIGIN VL, ALGRA A, VAN DEN BERGH WM, VERMEULEN M, VAN GIJN J: Calcium antagonists for aneurysmal subarachnoid hemorrhage. Cochrane Database Syst. Rev. (2005) (1):CD000277.
25. PICKARD JD, MURRAY GD, ILLINGWORTH R et al.: Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British Aneurysm Nimodipine trial. Br. Med. J. (1989) 298:636-642.
26. RAM CVS: Antihypertensive drugs. An overview. Am. J. Cardiovasc. Drugs (2002) 2:77-89.
27. ABERNETHY DR, SCHWARTZ JB: Calcium antagonist drugs. N. Engl. J. Med. (1999) 341:1447-1457.
28. PARR MJ, FINFER SR, MORGAN MK: Reversible cardiogenic chock complicating subarachnoid hemorrhage. Br. Med. J. (1996) 313:681-683.
29. SINGHAL AB, TOPCUOGLU MA, DORER DJ, OGILVY CS, CARTER BS, KOROSHETZ WJ: SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage. Neurology (2005) 64:1008-1013.
30. TOUYZ RM, SCHIFFRIN EL: Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol. Rev. (2000) 52:639-672.
31. CULMAN J, BLUME A, GOHLKE P, UNGER T: the renin angiotensin system in the brain: Possible therapeutic implications for AT1-receptor blockers. J. Human Hypertension (2002) 16: S64-S70.
32. IADECOLA C, GORELICK PB: hypertension, angiotensin, and stroke: Beyond blood pressure. Stroke (2004) 35:348-350.
33. FREEMAN EJ, CHISOLM GM, TALLANT EA: Role of calcium and protein kinase C in the activation of phospholipase D by angiotensin II in vascular smooth muscle cells. Arch. Biochem. Biophys. (1995) 319:84-92.
34. IPLIKCIOGLU AC, BAYAR MA, SAV A, ERBENGI T: Angiotensin-converting enzyme inhibitor cilazapril prevents chronic morphologic vasospasm in rat. Surg. Neurol. (1994) 41:294-298.
35. HONDA Y, MINATO H, FUJITANI B, MASUDA Y, HOSOKI K: Alacepril, an angiotensin-converting enzyme inhibitor, prevents cerebral vasospasm in subarachnoid hemorrhage model in rats. Methods Find. Exp. Clin. Pharmacol. (1997) 19:699-706 (Abstract).
36. FASSOT C, LAMBERT G, ELGHOZI JL, LAMBERT E: Impact of the renin-angiotensin system on cerebral perfusion following subarachnoid hemorrhage in the rat. J. Physiol. (2001) 535:533-540.
37. FASSOT C, LAMBERT G, GAUDET-LAMBERT E, FRIBERG P, ELGHOZI JL: Beneficial effect of renin-angiotensin system for maintaining blood pressure control following subarachnoid hemorrhage. Brain Res. Bull (1999) 50:127-132.
38. HAMANN G, STOBER T, SCHIMRIGK K: Has plasma renin activity a prognostic significance in subarachnoid hemorrhage? Acta Neurochir. (1989) 100:25-30.
39. OHKUMA H, OGANE K, FUJITA S, MANABE H, SUZUKI S:.Impairment of anti-platelet-aggregating activity of endothelial cells after experimental subarachnoid hemorrhage. Stroke (1993) 24:1541-1545.
40. OHKUMA H, SUZUKI S, KIMURA M, SOBATA E: Role of platelet function in symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke (1991) 22:854-859.
41. JUVELA S: Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J. Neurosurg. (1995) 82:480-484.
42. TOUSSAINT LG 3rd, FRIEDMAN JA, WIJDICKS EF et al.: Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage. J. Neurosurg. (2004) 101:921-925.
43. HOP JW, RINKEL GJ, ALGRA A, BERKELBACH VAN DER SPRENKEL JW, VAN GIJN J: Randomized pilot trial of postoperative aspirin in subarachnoid hemorrhage. Neurology (2000) 54:872-878.
44. BACHMAN DS: Discontinuing chronic aspirin therapy: Another risk factor stroke? Ann. Neurol. (2001) 51:137-138.
45. SHIBATA S, CHENG JB, MURAKAMI W: Reactivity of isolated human cerebral arteries to biogenic amines. Blood Vessels (1977) 14:356-365.
46. SINGHAL AB, CAVINESS VS, BEGLEITER AF, MARK EJ, RORDORF G, KOROSHETZ WJ: Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology (2002) 58:130-133.
47. SVENDGAARD NA, EDVINSSON L, OWMAN C, SAHLIN C: Increased sensitivity of the basilar artery to norepinephrine and 5-hydroxytryptamine following experimental subarachnoid hemorrhage. Surg. Neurol. (1977) 8:191-195.
48. MIRANDA FJ, ALABADI JA, TERROGROSA G et al.: Modulatory role of endothelial and nonendothelial nitric oxide in 5-hydroxytryptamine-induced contraction in cerebral arteries after subarachnoid hemorrhage. Neurosurgery (1996) 39:998-1004.
49. HANSEN-SCHWARTZ J: Receptor changes in cerebral arteries after subarachnoid hemorrhage. Acta Neurol. Scand. (2004) 109:33-44.
50. KAUFMAN MJ, LEVIN JM, ROSS MH et al.: Cocaine induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. JAMA (1998) 279:367-380.
51. CONWAY JE, TAMARGO RJ: Cocaine use is an independent risk factor for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke (2001) 32:2338-2343.
52. HOWINGTON JU, KUTZ SC, WILDING GE, AWASTHI D: Cocaine use as a predictor of outcome in aneurysmal subarachnoid hemorrhage. J. Neurosurg. (2003) 99:271-275.
53. FERRARI-DILEO G, POTTER L: Adrenoreceptors and muscarinic receptors in human pial arteries and microvessels: a receptor binding study. J. Cereb. Blood Flow Metab. (1985); 5:458-464.
54. MILLER JA, DACEY RG JR, DIRINGER MN: Safety of hypertensive hypervolemic therapy with phenylephrine in the treatment of delayed ischemic deficits after subarachnoid hemorrhage. Stroke (1995) 26:2260-2266.
55. ENDRES M, LAUFS U: Effects of statins on endothelium and signaling mechanisms. Stroke (2004) 35(Suppl. I):2708-2711.
56. MCGIRT MJ, LYNCH J, PARRA A et al.: Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke (2002) 33:2950-2956.
57. JUNG KH, CHU K, JEONG SW et al.: HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke (2004) 35:1744-1749.
58. PARRA A, KREITER KT, WILLIAMS S et al.: Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery (2005) 56:476-484.
59. HEESCHEN C, HAMM CW, LAUFS U, SNAPINN S, BOHM M, WHITE HD: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation (2002) 105:1446-1452.
60. THOMAS M, MANN J: Increased thrombotic vascular events after change of statin. Lancet (1998) 352:1830-1831.
61. TSENG MY, CZOSNYKA M, RICHARDS H, PICKARD JD, KIRKPATRICK PJ: Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage. A Phase II randomized placebo-controlled trial. Stroke (2005) 36:1627-1632.
62. AYATA C, BADJATIA N, CHOU S et al.: A randomized, double-blind, placebo-controlled trial of simvastatin on subarachnoid hemorrhage-induced vasospasm. Neurocritical care society 3rd Annual Meeting of the Scottsdale Hilton & Villas Scottsdale, Arizona, 25-27 February (2005). (Abstract).
63. LYNCH JR, WANG H, MCGIRT MJ et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage. Results of a pilot randomized clinical trial. Stroke (2005) In press.
64. KISTLER JP, LEES RS, CANDIA G, ZERVAS NT, CROWELL RM, OJEMANN RG: Intravenous nitroglycerin in experimental vasospasm. A preliminary report. Stroke (1979) 10:26-29.
65. EGEMEN, N, TURKER, R, SANLIDILEK U et al.: The effect of intrathecal sodium nitroprusside on severe chronic vasopasm. Neurol. Res. (1993) 15:310-315.
66. ITO Y, ISOTANI E, MIZUNO Y, AZUMA H, HIRAKAWA K: Effective improvement of the cerebral vasospasm after subarachnoid hemorrhage with low-dose nitroglycerin. J. Cardiovasc. Pharmacol. (2000) 35:45-50.
67. LESLEY WS, LAZO A, CHALOUPKA JC, WEIGELE JB: Successful treatment of cerebral vasospasm by use of transdermal nitroglycerin ointment (Nitropaste). AJNR Am. J. Neuroradiol. (2003) 24:1234-1236.
68. REINERT M, WIEST R, BARTH L, ANDRES R, OZDOBA C, SEILER R. Transdermal nitroglycerin in patients with subarachnoid hemorrhage. Neurol. Res. (2004) 26:435-439.